Switch theme
Sign up to access all valuation multiples
Onconic Therapeutics Inc is a company that researches and develops new drugs for gastrointestinal diseases and anticancers, which have large unmet medical needs. Its pipeline products are Zataprazan(OCN-101) and OCN-201.
2020
n/a
LTM Revenue n/a
LTM EBITDA n/a
$149M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Onconic Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Onconic Therapeutics achieved revenue of $10.1M and an EBITDA of -$6.0M.
Onconic Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Onconic Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $14.3M | $10.1M | XXX | XXX | XXX |
| Gross Profit | $0.1M | $14.3M | XXX | XXX | XXX |
| Gross Margin | 0% | 142% | XXX | XXX | XXX |
| EBITDA | $2.0M | -$6.0M | XXX | XXX | XXX |
| EBITDA Margin | 14% | -59% | XXX | XXX | XXX |
| Net Profit | -$9.8M | $1.1M | XXX | XXX | XXX |
| Net Margin | -69% | 11% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Onconic Therapeutics's stock price is KRW 24200 (or $16).
Onconic Therapeutics has current market cap of KRW 261B (or $178M), and EV of KRW 219B (or $149M).
See Onconic Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $149M | $178M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Onconic Therapeutics has market cap of $178M and EV of $149M.
Onconic Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Onconic Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Onconic Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $149M | XXX | XXX | XXX |
| EV/Revenue | 14.7x | XXX | XXX | XXX |
| EV/EBITDA | -24.8x | XXX | XXX | XXX |
| P/E | -32.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -27.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOnconic Therapeutics's NTM/LTM revenue growth is n/a
Onconic Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Onconic Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Onconic Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Onconic Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -30% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -59% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -405% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 74% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 132% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Onconic Therapeutics acquired XXX companies to date.
Last acquisition by Onconic Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Onconic Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Onconic Therapeutics founded? | Onconic Therapeutics was founded in 2020. |
| Where is Onconic Therapeutics headquartered? | Onconic Therapeutics is headquartered in South Korea. |
| Is Onconic Therapeutics publicy listed? | Yes, Onconic Therapeutics is a public company listed on KRX. |
| What is the stock symbol of Onconic Therapeutics? | Onconic Therapeutics trades under 476060 ticker. |
| When did Onconic Therapeutics go public? | Onconic Therapeutics went public in 2024. |
| Who are competitors of Onconic Therapeutics? | Similar companies to Onconic Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Onconic Therapeutics? | Onconic Therapeutics's current market cap is $178M |
| What is the current revenue growth of Onconic Therapeutics? | Onconic Therapeutics revenue growth between 2023 and 2024 was -30%. |
| Is Onconic Therapeutics profitable? | Yes, Onconic Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
